Endurant Capital Management LP - Q1 2018 holdings

$268 Million is the total value of Endurant Capital Management LP's 69 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .

 Value Shares↓ Weighting
AGN BuyALLERGAN PLC$17,231,000
+37.7%
102,391
+33.9%
6.44%
+68.3%
ABT BuyABBOTT LABS$16,582,000
+102.6%
276,732
+93.0%
6.19%
+147.7%
JNJ BuyJOHNSON & JOHNSON$14,623,000
+72.1%
114,111
+87.7%
5.46%
+110.3%
MDT BuyMEDTRONIC PLC$10,839,000
+15.4%
135,115
+16.2%
4.05%
+41.0%
BDX BuyBECTON DICKINSON & CO$10,625,000
+147.3%
49,030
+144.3%
3.97%
+202.3%
BSX BuyBOSTON SCIENTIFIC CORP$10,592,000
+24.7%
387,698
+13.2%
3.96%
+52.4%
UHS NewUNIVERSAL HLTH SVCS INCcl b$9,875,00083,400
+100.0%
3.69%
UNH BuyUNITEDHEALTH GROUP INC$9,717,000
+14.0%
45,408
+17.5%
3.63%
+39.3%
ANTM BuyANTHEM INC$9,690,000
+91.3%
44,105
+95.9%
3.62%
+133.9%
MRK BuyMERCK & CO INC$9,407,000
+57.6%
172,700
+62.8%
3.51%
+92.5%
SHPG BuySHIRE PLCsponsored adr$8,066,000
+59.0%
53,996
+65.1%
3.01%
+94.4%
SYNH NewSYNEOS HEALTH INCcl a$6,830,000192,400
+100.0%
2.55%
CVS BuyCVS HEALTH CORP$6,477,000
+67.6%
104,111
+95.3%
2.42%
+104.8%
MYL BuyMYLAN N V$6,443,000
+28.1%
156,487
+31.6%
2.41%
+56.6%
LH BuyLABORATORY CORP AMER HLDGS$4,784,000
+45.8%
29,575
+43.7%
1.79%
+78.2%
HCA NewHCA HEALTHCARE INC$4,346,00044,800
+100.0%
1.62%
GILD NewGILEAD SCIENCES INC$3,558,00047,200
+100.0%
1.33%
CI BuyCIGNA CORPORATION$3,455,000
+751.0%
20,600
+930.0%
1.29%
+941.1%
MASI NewMASIMO CORP$1,838,00020,900
+100.0%
0.69%
INCY BuyINCYTE CORP$1,618,000
+130.2%
19,420
+161.7%
0.60%
+180.9%
PPH NewVANECK VECTORS ETF TRpharmaceutical$1,449,00025,500
+100.0%
0.54%
PKI BuyPERKINELMER INC$1,442,000
+109.6%
19,041
+102.5%
0.54%
+156.7%
VRX NewVALEANT PHARMACEUTICALS INTL$1,356,00085,200
+100.0%
0.51%
A NewAGILENT TECHNOLOGIES INC$1,338,00020,000
+100.0%
0.50%
DGX NewQUEST DIAGNOSTICS INC$1,304,00013,000
+100.0%
0.49%
ARRY BuyARRAY BIOPHARMA INC$1,165,000
+79.8%
71,400
+41.1%
0.44%
+119.7%
OCUL NewOCULAR THERAPEUTIX INC$1,162,000178,461
+100.0%
0.43%
ICLR NewICON PLC$992,0008,400
+100.0%
0.37%
BLCM NewBELLICUM PHARMACEUTICALS INC$947,000144,300
+100.0%
0.35%
TFX NewTELEFLEX INC$918,0003,600
+100.0%
0.34%
JAZZ BuyJAZZ PHARMACEUTICALS PLC$770,000
+15.4%
5,100
+3.0%
0.29%
+41.2%
XRAY NewDENTSPLY SIRONA INC$664,00013,200
+100.0%
0.25%
QGEN NewQIAGEN NV$662,00020,500
+100.0%
0.25%
VKTX NewVIKING THERAPEUTICS INC$520,000119,100
+100.0%
0.19%
RETA NewREATA PHARMACEUTICALS INCcl a$513,00025,000
+100.0%
0.19%
AVDL NewAVADEL PHARMACEUTICALS PLCsponsored adr$406,00055,700
+100.0%
0.15%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LABORATORY CORP AMER HLDGS31Q2 20238.7%
ELEVANCE HEALTH INC29Q3 20238.8%
BECTON DICKINSON & CO28Q2 20239.8%
MCKESSON CORP27Q1 20234.4%
CENCORA INC26Q3 20235.9%
HOLOGIC INC24Q3 20237.5%
JOHNSON & JOHNSON24Q4 20215.5%
ZIMMER HLDGS INC23Q3 20237.5%
BOSTON SCIENTIFIC CORP22Q3 20235.5%
DAVITA INC22Q1 20214.9%

View Endurant Capital Management LP's complete holdings history.

Latest significant ownerships (13-D/G)
Endurant Capital Management LP Q1 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AZIYO BIOLOGICS, INC.March 21, 2023576,2534.9%
Oxford Immunotec Global PLCSold outFebruary 17, 202100.0%

View Endurant Capital Management LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-07
SC 13D/A2024-04-10
13F-HR2024-02-14
13F-HR2023-11-14
SC 13D/A2023-09-08
13F-HR2023-08-14
3/A2023-05-24
13F-HR2023-05-15
32023-05-15
SC 13D2023-05-15

View Endurant Capital Management LP's complete filings history.

Compare quarters

Export Endurant Capital Management LP's holdings